1.78 USD
▲+0.02+1.23%
盘后 1.91 0.00%
2026-09-16
市值
$23.08M
市盈率
—
EPS
-2.77
股息率
—
52 周区间
1.50 – 43.65
成交量
75.29K
Beta
—
目标价
9.50
52W 低 1.5052W 高 43.65
价格走势
公司简介
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI...